United Therapeutics Corporation $UTHR Shares Sold by LSV Asset Management

LSV Asset Management decreased its position in United Therapeutics Corporation (NASDAQ:UTHR) by 40.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 408,065 shares of the biotechnology company’s stock after selling 278,645 shares during the period. LSV Asset Management’s holdings in United Therapeutics were worth $198,830,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Torren Management LLC acquired a new stake in shares of United Therapeutics in the fourth quarter valued at $26,000. Activest Wealth Management lifted its holdings in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the period. WealthCollab LLC lifted its holdings in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. lifted its holdings in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares during the period. Finally, Entrust Financial LLC acquired a new stake in shares of United Therapeutics in the fourth quarter valued at $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on UTHR shares. HC Wainwright boosted their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Royal Bank Of Canada cut their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Finally, Raymond James Financial started coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price on the stock. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

Insider Buying and Selling at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $9,956,712.48. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michael Benkowitz sold 14,440 shares of the company’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $472.13, for a total value of $6,817,557.20. The disclosure for this sale is available in the SEC filing. Insiders have sold 569,913 shares of company stock worth $317,603,631 over the last three months. 8.60% of the stock is owned by insiders.

United Therapeutics Stock Up 0.5%

Shares of United Therapeutics stock opened at $568.43 on Friday. The stock’s fifty day moving average is $563.25 and its 200-day moving average is $511.57. The firm has a market capitalization of $24.13 billion, a PE ratio of 20.98, a price-to-earnings-growth ratio of 1.83 and a beta of 0.60. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period last year, the firm earned $6.63 earnings per share. Analysts expect that United Therapeutics Corporation will post 27.07 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.